Sucampo and Takeda's Newly Approved IBS Drug Is Sexy To Investors
-
Font Size:
On a disease sexiness scale from 0-100, chronic idiopathic constipation (CIC) and irritable bowel syndrome (IBS-c) are close to rounding out the bottom of that range. However, they remain important medical problems.
CIC accounts for roughly 6 million related outpatient visits each year and just over a quarter million hospital admissions with constipation as the primary diagnosis. In addition, an estimated 12 million Americans suffer from IBS-c and many have symptoms for a decade. Since the withdrawal of the 5-HT4 agonist, Zelnorm (tegaserod), by Novartis (NVS) in March of last year due to possible heart risks, there has been no approved therapy for IBS-c.
Amitiza (lubiprostone), from Sucampo (SCMP) and Takeda (TKPHF.PK), a chloride channel activator that works in the small bowel and has already been approved by the FDA for CIC, yesterday was approved for the treatment of IBS-c. The drugs is safe (though does have an adverse event [AE] nausea rate of ~30%), effective, and most importantly from a safety standpoint, is not absorbed.
It has always puzzled me why its sales have lagged behind expectations (only $48m in ‘06 and $154m in ‘06). I’ve always assumed the reason was the AE nausea combined with a slow marketing ramp-up and hoped that it wasn’t that physicians were scared away from prescribing therapies after the Zelnorm fiasco (I generally give physicians more credit than that).
Since Zelnorm was only approved to treat IBS-c, the sales numbers, until now, weren’t directly comparable, but I’m interested in seeing the year-end increase in sales to tease out the meaning behind the initially poor revenues. In its final year, Zelnorm sold almost $500m and was well on its way of surpassing that mark before being killed; I would expect the numbers for Amitiza in the next few years to be higher than that.
I think Sucampo (which will also received a $50m milestone payment from Takeda, which holds the US rights) has a winner in Amitiza and so far, the market agrees. SCMP was up 38% (to 16.75) after an hour of trading on this morning's market.
Get Seeking Alpha Free Stock Alerts by Email!
Get Free Stock Alerts by Email!
-
Editor's Picks
-
Most Popular
- Assurant Is A Compelling Short Sell
- Broadcom Enters FTTH Chipset Market
- Another Macroshares Oil Arbitrage Opportunity
- Freeport McMoran: With Copper Prices Rising, It's Still a Buy
- Oil and the Futures Market
- Three Ways to Cash In on Record Meat and Dairy Prices
- Full list of Editor's Picks »
- High Likelihood of a Market Crash »
- Time To Start Buying Some Dogs? »
- Sirius-XM Combination: A Future Microsoft Acquisition? »
- JP Morgan Offer for Wachovia Makes Sense »
- High-Yield Canadian Royalty Trusts: What's the Catch? »
- Adding to My GE Position »
- 7 Stocks for a High Yield Cash Flow Portfolio »
- Nokia: Bargain of a Lifetime - Barron's »
- Top 10 Payout Yield Stocks »
- Wall Street Breakfast: Must-Know News »
- Drybulk Shipping: Prepare for a New Record High »
-
Long Ideas
-
Short Ideas
-
Cramer's Picks
- Big Lots, Wal-Mart and Costco: 3 Musketeers of the Pooring of America
- What's Behind Hansen's Smackdown?
- The Long Case for China Medical Technologies
- ASA Limited: A Golden Opportunity
- ValueClick: Has the Hunted Become the Hunter?
- Petrohawk and Chesapeake Fly on Haynesville Shale News
- StanCorp a Safe Financial - Cramer's Lightning Round (7/2/08)
- GM on the Skids - Fast Money Recap (7/2/08)
- Three Ways to Cash In on Record Meat and Dairy Prices
- Momentum Stocks Stalled - Cramer's Stop Trading! (7/3/08)
- Full list of Long Ideas »
- Crystal River’s Q2 Write-Downs Could Bankrupt the Company
- Assurant Is A Compelling Short Sell
- Fuel Systems Solutions: Time to Take Profits
- GM an Unlikely Hero - Fast Money Recap (7/1/08)
- Pair Trade Visa and Capital One
- Amazon's Kindle Numbers: All Fluff, Zero Substance
- A. Schulman: Cashless Profits
- Titan Machinery: Doesn't Anybody Look at Valuation?
- Goodrich Petroleum: Gas in the Ground Doesn't Mean Cash in the Bank
- Outlook Remains Grim for MBIA, Ambac
- Full list of Short Ideas »
- StanCorp a Safe Financial - Cramer's Lightning Round (7/2/08)
- Momentum Stocks Stalled - Cramer's Stop Trading! (7/3/08)
- Expecting a Lift for Pediatrix: Cramer's Mad Money (7/3/08)
- The Most Bullish Thing - Cramer's Stop Trading! (7/1/08)
- Exelon's Got Nukes - Cramer's Lightning Round (7/1/08)
- Prescription Prediction for Allscripts - Cramer's Mad Money (7/1/08)
- Rex Marks the Spot - Cramer's Lightning Round, (6/30/08)
- Medicare Bill Buys - Cramer's Mad Money (6/30/08)
- Cracker Bottom of the Barrel - Cramer's Lightning Round (6/27/08)
- Britannia Bulk Rules the Waves - Cramer's Mad Money (6/27/08)
- Full list of Cramers Picks »
Most Popular Feeds
-
ETFs
-
US Market
-
Long Ideas
-
Alt. Energy
- Full list of feeds »
Hedge Fund Jobs
Job Seekers:
- Search jobs by category
- Get job alerts by email or live feed
- Apply online
Employers
- See all recruitment options
- Get applications online or by email



This article has 1 comment:
Too many constraints on marketing expense, is this the reason?